LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Home・Akciju saraksts・10X Genomics Inc (Class A)

10X Genomics Inc (Class A)

Slēgts

SektorsVeselības aprūpe

20.83 1.71

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

20.18

Max

21.18

Galvenie mērījumi
By Trading Economics
Ienākumi	2.8M -13M
Pārdošana	-15M 151M
EPS	0.072
Peļņas marža	-8.93
Darbinieki	1,178
EBITDA	2.5M -17M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+18.1% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 6. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-190M 2.6B
Iepriekšējā atvēršanas cena	19.12
Iepriekšējā slēgšanas cena	20.83

Ziņu noskaņojums

By Acuity

13%

87%

18 / 346 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

8.32 / 8.63 Atbalsts un pretestība

10X Genomics Inc (Class A) Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 12. maijs 22:50 UTC

Peļņas

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

2026. g. 12. maijs 22:49 UTC

Peļņas

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

2026. g. 12. maijs 22:32 UTC

Peļņas

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

2026. g. 12. maijs 23:48 UTC

Tirgus saruna

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

2026. g. 12. maijs 22:57 UTC

Tirgus saruna

Peļņas

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

2026. g. 12. maijs 22:26 UTC

Peļņas

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

2026. g. 12. maijs 22:25 UTC

Peļņas

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

2026. g. 12. maijs 22:25 UTC

Peļņas

Aristocrat Leisure Interim Dividend A$0.50/Security

2026. g. 12. maijs 22:24 UTC

Peļņas

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

2026. g. 12. maijs 22:23 UTC

Peļņas

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

2026. g. 12. maijs 22:23 UTC

Peļņas

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

2026. g. 12. maijs 22:19 UTC

Peļņas

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

2026. g. 12. maijs 22:14 UTC

Peļņas

CBA: Business Lending Continued to Grow Above System>CBA.AU

2026. g. 12. maijs 22:14 UTC

Peļņas

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

2026. g. 12. maijs 22:13 UTC

Peļņas

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

2026. g. 12. maijs 22:12 UTC

Peļņas

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

2026. g. 12. maijs 22:12 UTC

Peļņas

CBA 3Q New Home Loan Funding A$45B>CBA.AU

2026. g. 12. maijs 22:11 UTC

Peļņas

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

2026. g. 12. maijs 22:11 UTC

Peļņas

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

2026. g. 12. maijs 22:10 UTC

Peļņas

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

2026. g. 12. maijs 22:09 UTC

Peļņas

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

2026. g. 12. maijs 22:09 UTC

Peļņas

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

2026. g. 12. maijs 22:08 UTC

Peļņas

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

2026. g. 12. maijs 22:07 UTC

Peļņas

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

2026. g. 12. maijs 22:06 UTC

Peļņas

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

2026. g. 12. maijs 22:06 UTC

Peļņas

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

2026. g. 12. maijs 22:05 UTC

Peļņas

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

2026. g. 12. maijs 22:04 UTC

Peļņas

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

2026. g. 12. maijs 22:04 UTC

Peļņas

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

2026. g. 12. maijs 22:04 UTC

Peļņas

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Salīdzinājums

Cenas izmaiņa

10X Genomics Inc (Class A) Prognoze

Cenas mērķis

By TipRanks

18.1% augšup

Prognoze 12 mēnešiem

Vidējais 24.21 USD 18.1%

Augstākais 32 USD

Zemākais 20 USD

Pamatojoties uz 13 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi 10X Genomics Inc (Class A) — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

13 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 13 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam 10X Genomics Inc (Class A) — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

8.32 / 8.63Atbalsts un pretestība

Recent bullish events outweigh bearish events.

There are no events.

Noskaņojums

By Acuity

18 / 346 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par 10X Genomics Inc (Class A)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.